Apr 30, 2026 08:31AM
Apr 30, 2026 08:30AM
Apr 30, 2026 08:00AM
Apr 28, 2026 04:05PM
Feb 26, 2026 04:05PM
Feb 10, 2026 06:53AM
Feb 4, 2026 08:02AM OPKO Health and Entera Bio expand partnership for oral PTH tablet
Feb 4, 2026 08:00AM
Oct 29, 2025 04:05PM
Sep 15, 2025 08:32AM
Sep 15, 2025 08:30AM
Jul 31, 2025 04:05PM
Jul 8, 2025 08:03AM
Jul 8, 2025 08:00AM OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
Jun 25, 2025 08:05AM
Jun 25, 2025 08:00AM
Mar 19, 2025 06:41AM
Mar 17, 2025 08:01AM
Mar 17, 2025 08:00AM
Mar 11, 2025 07:07AM
Mar 11, 2025 07:00AM Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses
Jan 27, 2025 08:00AM
Jan 8, 2025 09:27AM
Jan 7, 2025 08:00AM
Nov 8, 2024 04:05PM
Nov 7, 2024 08:00AM
Sep 25, 2024 08:31AM
Sep 25, 2024 08:30AM Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
Sep 16, 2024 07:30AM
Aug 9, 2024 04:05PM
Aug 7, 2024 04:06PM
May 7, 2024 04:05PM
Mar 28, 2024 08:01AM
Mar 28, 2024 08:00AM
Mar 20, 2024 08:00AM Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
Nov 2, 2023 10:00AM
Oct 25, 2023 04:25PM
Sep 12, 2023 08:31AM
Sep 12, 2023 08:30AM
Aug 3, 2023 04:05PM
Jun 28, 2023 06:45AM
Jun 28, 2023 06:45AM FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency
May 3, 2023 04:05PM
Mar 9, 2023 08:13AM
Mar 8, 2023 08:03AM
Mar 8, 2023 08:00AM
Feb 23, 2023 04:05PM
Feb 9, 2023 07:05AM
Nov 8, 2022 04:05PM OPKO Health Reports Third Quarter 2022 Business Highlights and Financial Results
Mar 1, 2022 06:00AM

322,137 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All